The preliminary merger agreement between the corporation and Metsera Inc., a startup developing peptide-based GLP-1 weight-loss drugs, was valued at $7.3 billion. However, on the final day of the deal, Danish competitor Novo Nordisk A/S submitted a $10 billion offer, sparking a bidding war for the promising company. On Wednesday, Novo Nordisk A/S offered $62.2 per Metsera Inc. share with an additional $24 per share possible from future milestones, while Pfizer’s counterbid reached $70 per share — valuing the total at about $8.1 billion. Markets now await further bids from both sides.
According to the company’s financial report, third-quarter revenue came in at $16.7 billion, slightly below forecasts of $16.8 billion and down from $17.7 billion a year earlier. Earnings per share stood at $0.87, compared to $0.66 and $1.06 in the same period of previous years.
Support and Resistance Levels
On the daily chart, the instrument is trading above the lower boundary of an ascending channel with dynamic limits at 27.80–24.30.
Technical indicators maintain a sell signal: the fast EMAs of the Alligator indicator remain below the signal line, keeping a narrow fluctuation range, while the Awesome Oscillator (AO) histogram stays below the zero line.
Support levels: 23.91, 21.98.
Resistance levels: 25.17, 27.32.
Trading Scenarios and Pfizer Price Forecast
Short positions can be opened after a decline and consolidation below 23.91 with a target of 21.98 and a stop-loss at 24.40. Estimated time horizon: 7 days or more.
Long positions can be considered after a rise and consolidation above 25.17 with a target of 27.32 and a stop-loss below 24.20.
Scenario
| Timeframe | Weekly |
| Recommendation | SELL STOP |
| Entry Point | 23.90 |
| Take Profit | 21.98 |
| Stop Loss | 24.40 |
| Key Levels | 21.98, 23.91, 25.17, 27.32 |
Alternative Scenario
| Recommendation | BUY STOP |
| Entry Point | 25.20 |
| Take Profit | 27.32 |
| Stop Loss | 24.20 |
| Key Levels | 21.98, 23.91, 25.17, 27.32 |